Zymeworks (ZYME) announced achievement of a $14M cash research milestone from GSK (GSK) associated with a clinical milestone. “In April 2016, ...
Clinical validation of the Azymetric platform is demonstrated by the accelerated approval of Ziihera® (zanidatamab-hrii), a treatment for advanced HER2-positive biliary tract cancer in adults who have ...
Zymeworks Inc. (NYSE:ZYME – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms ...
Hosted on MSN11mon
Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock?Zymeworks Inc. (ZYME) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...
VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology ...
Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Zymeworks in a note issued to ...
Zymeworks (NYSE:ZYME) came into focus in late December when major shareholder EcoR1 Capital increased its stake. Already a 10% holder and board member, EcoR1 made several purchases in December and ...
Vancouver, BC, February 12, 2025--(T-Net)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, announced that it has entered ...
Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback